Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Libtayo
Biotech
Replimune shares halve as skin cancer drug fails phase 2
Replimune’s skin cancer med is an “active agent” according to CEO Philip Astley-Sparke, but it didn’t achieve the main goals of a phase 2 trial.
Annalee Armstrong
Dec 5, 2023 10:35am
Regeneron rethinks CD28 bispecific R&D plan after 2 patients die
Aug 3, 2023 8:09am
Have mRNA cancer vaccines arrived? Biopharma execs weigh in
Jan 25, 2023 10:30am
BioNTech-Regeneron add 3rd tumor type to cancer vaccine research
Mar 8, 2022 11:47am